2-Methyl-4--acetanilid | 1459-54-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Methyl-4--acetanilid
• 英文别名: N-(4-adamantanyl-2-methylphenyl)acetamide；N-[4-(1-adamantyl)-2-methylphenyl]acetamide
• CAS: 1459-54-7
• 化学式: C₁₉H₂₅NO
• 分子量: 283.414
• InChiKey: NFJANHJZPRVNOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Methyl-4--acetanilid 在 盐酸 作用下， 生成 2-Methyl-4--anilin
  参考文献：
  名称：

  Stetter,H. et al., Chemische Berichte, 1964, vol. 97, p. 3488 - 3492

  摘要：

  DOI：
• 作为产物：
  描述：

  1-溴金刚烷 、 2-甲基乙酰苯胺 生成 2-Methyl-4--acetanilid
  参考文献：
  名称：

  Stetter,H. et al., Chemische Berichte, 1964, vol. 97, p. 3488 - 3492

  摘要：

  DOI：

文献信息

• PLANT GROWTH REGULATOR
  申请人：University of Washington

  公开号：US20210235697A1

  公开（公告）日：2021-08-05

  Providing an auxin derivative that can exert its intended effect more efficiently, while reducing any unintended effects. A compound represented by the General Formula (1) having a specific substituent at the 5- and/or 6-position of the auxin indole ring.

  提供一种能够更有效地发挥预期效果并减少任何意外效果的生长素衍生物。一种由通用式（1）表示的化合物，在生长素吲哚环的5-和/或6-位置具有特定取代基。
• Adamantylation of N-aryl and N-arylalkyl acetamides in trifluoroacetic acid
  作者：I. A. Novakov、B. S. Orlinson、D. V. Zavyalov、V. I. Porkhun、E. N. Savelyev、E. A. Potaenkova、O. V. Vostrikova、M. A. Nakhod、A. V. Kireeva、A. M. Pichugin

  DOI：10.1007/s11172-020-2873-9

  日期：2020.6

  Alkylation of N-aryl and N-arylalkyl acetamides with hydroxy adamantane derivatives in trifluoroacetic acid was studied. The differentiating effect of trifluoroacetic acid on the regio-selectivity of adamantylation of o-alkyl-substituted acetanilides was established, leading to energetically more stable products of para-substitution with respect to the alkyl group (the content of para-alkyl isomers

  研究了 N-芳基和 N-芳基烷基乙酰胺与羟基金刚烷衍生物在三氟乙酸中的烷基化反应。确定了三氟乙酸对邻烷基取代乙酰苯胺的金刚烷基化区域选择性的差异化作用，导致相对于烷基的对位取代产物在能量上更稳定（对位烷基异构体的含量为 93– 94%）。这能够以 83-99% 的产率和 95-99% 的纯度合成金刚烷基氨基芳烃。
• Pharmaceutical use of substituted amides
  申请人：Andersen Sune Henrik

  公开号：US20060111366A1

  公开（公告）日：2006-05-25

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  本文介绍了使用取代酰胺来调节11β-羟化甾体脱氢酶1型（11βHSD1）的活性以及将这些化合物用作制药组合物的方法。还介绍了一类新型的取代酰胺，它们在治疗中的应用、包含这些化合物的制药组合物以及它们在药物制剂制造中的应用。这些化合物是11βHSD1的调节剂，更具体地说是抑制剂，可用于治疗、预防和/或预防一系列需要降低活性糖皮质激素细胞内浓度的医学疾病。
• Amide Derivatives and Pharmaceutical Use Thereof
  申请人：Andersen Henrik Sune

  公开号：US20090264414A1

  公开（公告）日：2009-10-22

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  本文描述了使用取代酰胺来调节11β-羟化类固醇脱氢酶1型（11βHSD1）活性以及这些化合物作为药物组分的用途。还描述了一类新型的取代酰胺，它们在治疗中的用途，包括含有这些化合物的药物组分以及它们在制造药物中的用途。这些化合物是调节剂，更具体地说是11βHSD1活性的抑制剂，可用于治疗、预防和/或预防一系列医学疾病，其中降低细胞内活性糖皮质激素的浓度是可取的。
• Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
  申请人：NOVO NORDISK A/S

  公开号：EP1854487A2

  公开（公告）日：2007-11-14

  Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.

  由 11β- 羟类固醇脱氢酶 1 型抑制剂和糖皮质激素受体激动剂组成的联合疗法，用于治疗某些形式的癌症、以炎症为组成部分的疾病和失调，并最大限度地减少与糖皮质激素受体激动剂疗法相关的副作用。